7 ZENKUDA 3Q ‘26 4Q ‘26 1Q ‘27 2Q ‘27 3Q ‘27 4Q ‘27 1Q ‘28 2Q ‘28 3Q ‘28 RVO (BEACON) DR (GLOW1) DR (GLOW2) wAMD (DAYLIGHT) wAMD (DAYBREAK) KSI-101 MESI (PEAK) MESI (PINNACLE) KSI-501 wAMD (DAYBREAK) DME (ALTO) Four Phase 3 readouts in 2026, if successful, position Kodiak to file 3 licensing applications (BLA) in 2026 and 2027 RVO: retinal vein occlusion; DR: diabetic retinopathy; AMD: age-related macular edema; DME: diabetic macular edema; MESI: macular edema secondary to inflammation; BLA: biologics license application; sBLA: supplemental biologics license application; DAYBREAK: NCT06556368; PEAK: NCT06990399; PINNACLE: NCT06996080 BLA* BLA* BLA* sBLA* • DAYBREAK topline data expected 3Q 2026 • Phase 3 ALTO study in DME First Patient In expected 3Q 2026 • Pivotal analysis 1 ( PEAK ) expected December 2026; potential licensing application in 1H 2027 • Pivotal analysis 2 ( PEAK+PINNACLE ) expected 2Q 2027 First Patient In (Expected) • DAYBREAK topline data expected 3Q 2026; licensing application in 4Q 2026 Upcoming catalysts (expected) 3 additional topline data readouts expected in 2026 4 successful pivotal studies completed 3 Licensing applications (BLA) expected in 2026 and 2027 *Timing reflects current expectations; BLA timing pending discussions with regulatory bodies, subject to change